Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.49 |
| ▸ | EDNRB | P24530 | 2/20 | 0.46 |
| ▸ | EDNRA | P25101 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11155347 | 0.98 | HSD11B1 (0.47) | HSD11B1EDNRBEDNRAALDH1A1SLC40A1 | |
| SCHEMBL14101134 | 0.84 | MYC (0.50) | ALDH1A1MYCTTR | |
| SCHEMBL10510571 | 0.83 | MYC (0.41) | HSD11B1EDNRAMYCTTR | |
| SCHEMBL7106883 | 0.83 | HSD11B1 (0.51) | HSD11B1EDNRBEDNRAALDH1A1SLC40A1 | |
| SCHEMBL27492603 | 0.81 | KMT2A (0.38) | HSD11B1ALDH1A1MYCMAPT | |
| SCHEMBL350041 | 0.81 | HSD11B1 (0.50) | HSD11B1EDNRBEDNRAALDH1A1SLC40A1 | |
| SCHEMBL2046745 | 0.81 | HSD11B1 (0.50) | HSD11B1EDNRBEDNRAALDH1A1SLC40A1 | |
| SCHEMBL3277048 | 0.81 | HSD11B1 (0.50) | HSD11B1EDNRBEDNRAALDH1A1SLC40A1 | |
| SCHEMBL618887 | 0.79 | HSD11B1 (0.49) | HSD11B1EDNRBEDNRAALDH1A1SLC40A1 | |
| SCHEMBL6038928 | 0.79 | HSD11B1 (0.49) | HSD11B1EDNRBEDNRAALDH1A1SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0884096-B1 | Semipermeable encapsulated membranes with improved acid and base stability process for their manufacture and their use | KOCH MEMBRANE SYSTEMS INC (US) | 2005-09-14 | — | — | EP | claimed |
| US-11898123-B2 | Cleaning compositions | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4204490-A1 | CLEANING COMPOSITIONS | FUJIFILM Electronic Materials U.S.A, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-RE49569-E1 | Alkylamine derivative | EA PHARMA CO., LTD. (JP) | 2023-07-04 | — | — | US | disclosed |
| CN-110054541-B | Preparation method of deuterated aromatic compound | 安徽秀朗新材料科技有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220145221-A1 | Cleaning Compositions | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. | 2022-05-12 | — | — | US | disclosed |
| US-20220064575-A1 | Cleaning Compositions | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. | 2022-03-03 | — | — | US | disclosed |
| EP-3774680-A1 | CLEANING COMPOSITIONS | FUJIFILM Electronic Materials U.S.A, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-111943912-A | Preparation method of 2-aminocinnamoyl alcohol ester derivative | 华侨大学 | 2020-11-17 | — | — | CN | disclosed |
| US-20200332231-A1 | Cleaning Compositions | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. | 2020-10-22 | — | — | US | disclosed |
| WO-2012125401-A1 | NOVEL ETCHING COMPOSITION | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120231632-A1 | Novel Etching Composition | FUJIFILM CORPORATION (JP) | 2012-09-13 | — | — | US | disclosed |
| US-7989640-B2 | Sulfonylpyrrolidine modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110015408-A1 | SULFONYLPYRROLIDINE MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-7820702-B2 | Nonsteroidal, nontoxic tissue selective modulators for side effect reduction; age-related and androgen-receptor related conditions such as sarcopenia; e.g. 4-(4-Hydroxy-1,1,3-trioxohexahydrothia-2,6a-diazapentalen-2-yl)-2-chloro-3-methylbenzonitrile | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1718626-A4 | SULFONYLPYRROLODINE MODULATORS OF ANDROGEN RECEPTOR FUCTION AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-1718626-A1 | SULFONYLPYRROLODINE MODULATORS OF ANDROGEN RECEPTOR FUCTION AND METHOD | Brystol-Myers Squibb Company (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005077925-A1 | SULFONYLPYRROLODINE MODULATORS OF ANDROGEN RECEPTOR FUCTION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050187267-A1 | Sulfonylpyrrolidine modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-25 | — | — | US | disclosed |
| EP-0038458-A1 | 4-Hydroxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide, their salts, their preparation and their utilization | Dr. Karl Thomae GmbH (DE) | 1981-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187267-A1 | Sulfonylpyrrolidine modulators of androgen receptor function and method | NR3C2, AR, NR4A3 | HSD11B1 92/4885EDNRB 180/4885EDNRA 184/4885 |
| US-20110015408-A1 | SULFONYLPYRROLIDINE MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | AR, NR5A1, NR4A1 | HSD11B1 95/4885EDNRB 163/4885EDNRA 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.